Editas Medicine Inc (EDIT)
5.64
-0.19
(-3.26%)
USD |
NASDAQ |
May 24, 16:00
5.64
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Research and Development Expense (TTM): 188.63M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 188.63M |
| December 31, 2023 | 177.65M |
| September 30, 2023 | 160.09M |
| June 30, 2023 | 160.91M |
| March 31, 2023 | 174.79M |
| December 31, 2022 | 174.96M |
| September 30, 2022 | 160.51M |
| June 30, 2022 | 148.45M |
| March 31, 2022 | 138.55M |
| December 31, 2021 | 142.51M |
| September 30, 2021 | 166.46M |
| June 30, 2021 | 171.11M |
| March 31, 2021 | 165.36M |
| December 31, 2020 | 158.00M |
| September 30, 2020 | 131.28M |
| June 30, 2020 | 120.07M |
| March 31, 2020 | 115.63M |
| December 31, 2019 | 96.90M |
| Date | Value |
|---|---|
| September 30, 2019 | 81.30M |
| June 30, 2019 | 76.04M |
| March 31, 2019 | 85.20M |
| December 31, 2018 | 90.66M |
| September 30, 2018 | 97.88M |
| June 30, 2018 | 100.84M |
| March 31, 2018 | 85.44M |
| December 31, 2017 | 83.16M |
| September 30, 2017 | 83.57M |
| June 30, 2017 | 74.01M |
| March 31, 2017 | 67.12M |
| December 31, 2016 | 56.98M |
| September 30, 2016 | 35.97M |
| June 30, 2016 | 28.99M |
| March 31, 2016 | 25.84M |
| December 31, 2015 | 18.85M |
| September 30, 2015 | 15.42M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
76.04M
Minimum
Jun 2019
188.63M
Maximum
Mar 2024
145.46M
Average
159.04M
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.209B |
| Bristol-Myers Squibb Co | 9.673B |
| Regeneron Pharmaceuticals Inc | 4.586B |
| Cabaletta Bio Inc | 64.94M |
| Oragenics Inc | 14.48M |